A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • Lenvatinib 18 mg combined with everolimus 5 mg was associated with manageable toxicity consistent with individual agents and no new safety signals. Observed activity warrants further evaluation of the combination in advanced RCC patients.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3889692

Digital Object Identifier (DOI)

  • 10.1007/s00280-013-2339-y

PubMed ID

  • 24190702

Additional Document Info

start page

  • 181

end page

  • 9

volume

  • 73

number

  • 1